Mirum Pharmaceuticals, Inc.

Drug pipeline (3)

Asset	Stage	Revenue	Trials	Status
Chenodiol	approved	—	0	—
Cholic acid	approved	—	2	approved
Maralixibat chloride	approved	—	9	approved

Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.

Clinical trials (34)

NCT ID	Phase	Status	Start	Completion	Sponsor name	Title
NCT03353454	phase3	withdrawn	2018-10-25	2020-06-15	Mirum Pharmaceuticals, Inc.	A Placebo-controlled Study of Maralixibat (SHP625) in Pediatric Subjects With Progressive Familial Intrahepatic Cholestasis (PFIC)
NCT04718961	phase2	terminated	2021-01-04	2022-12-07	Mirum Pharmaceuticals, Inc.	A Placebo-controlled Study of Volixibat in Subjects With Elevated Serum Bile Acids Associated With Intrahepatic Cholestasis of Pregnancy (OHANA)
NCT05050136	phase2	active_not_recruiting	2021-09-22	2027-01-01	Mirum Pharmaceuticals, Inc.	A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis
NCT04663308	phase2	active_not_recruiting	2020-12-18	2026-02-20	Mirum Pharmaceuticals, Inc.	A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)
NCT07712718	phase1	recruiting	2026-05-29	2026-07-01	Mirum Pharmaceuticals, Inc.	A Study to Evaluate the Absorption, Distribution, Metabolism, and Excretion of [14C]-MRM-3379

FDA applications (4)

Application

Type

Applicant

Products

NDA 205750

NDA

MIRUM PHARMACEUTICALS INC

NDA 214662

NDA

MIRUM PHARMACEUTICALS INC

NDA 219485

NDA

MIRUM PHARMACEUTICALS INC

NDA 219488

NDA

MIRUM PHARMACEUTICALS INC